US EditionWasatch Biolabs Expands Service Portfolio with Oxford Nanopore Assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control
Wasatch BioLabs adds three Oxford Nanopore assays to enhance pharmacogenomics and vaccine quality control, supporting precision medicine and accelerating drug development.
- On Oct. 6, 2025, Wasatch BioLabs announced it added three Oxford Nanopore research-use-only assays: a Pharmacogenomics panel, Telomere Sequencing, and mRNA Vaccine Quality Control.
- Targeting BioPharma and academic researchers, the new assays will support pharmacogenomics, telomere biology, and mRNA vaccine development for oncology, aging, and rare disease programs.
- Using long reads, the workflows provide molecule-level resolution and preserve poly tails, while the PGx panel offers full-gene coverage including repeats and structural variants.
- Leveraging its bioinformatics, WBL will run Oxford Nanopore assays through Wasatch BioLabs' high-capacity infrastructure, and Steve Abbott, COO, said `By integrating these Oxford Nanopore assays into our services, we're giving translational teams a way to adopt these powerful workflows with confidence`.
- Headquartered in a 20,000sqft CLIA-registered laboratory, Wasatch BioLabs as the largest U.S. long-read-only provider supports regulatory-ready development from discovery through lot release and stability studies.
11 Articles
11 Articles
Wasatch Biolabs expands service portfolio with Oxford Nanopore assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control
Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read sequencing, today announced the addition of three Oxford Nanopore-developed research-use-only (RUO) assays to its service portfolio: a Pharmacogenomics (PgX) panel, Telomere Sequencing, and mRNA Vaccine Quality Control.
mammothtimes.com
Wasatch BioLabs Expands Service Portfolio with Oxford Nanopore Assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control
SALT LAKE CITY, Oct. 6, 2025 /PRNewswire/ -- Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read sequencing, today announced the addition of three Oxford Nanopore–developed research-use-only (RUO) assays to its…
Wasatch Biolabs Expands Service Portfolio with Oxford Nanopore Assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control
Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read sequencing, today announced the addition of three Oxford Nanopore-developed research-use-only (RUO) assays to its service portfolio: a Pharmacogenomics (PgX) panel, Telomere Sequencing, and mRNA Vaccine Quality Control.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
